Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522556 | 0.94 | MAPK14 (0.43) | MAPK14MAPK11ENPP2TDP1L3MBTL1 | |
| SCHEMBL3525717 | 0.90 | MAPK14 (0.45) | MAPK14MAPK11L3MBTL1ALDH1A1PREP | |
| SCHEMBL3522481 | 0.90 | MAPK14 (0.44) | MAPK14MAPK11 | |
| SCHEMBL3519415 | 0.90 | MAPK14 (0.44) | MAPK14MAPK11ENPP2PTGDR2 | |
| SCHEMBL3521949 | 0.89 | MAPK14 (0.41) | MAPK14MAPK11ENPP2L3MBTL1PTGDR2 | |
| SCHEMBL3522555 | 0.87 | MAPK14 (0.42) | MAPK14MAPK11ENPP2 | |
| SCHEMBL4469329 | 0.87 | MAPK14 (0.44) | MAPK14ENPP2TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3522726 | 0.86 | MAPK14 (0.44) | MAPK14MAPK11L3MBTL1PTGDR2ALDH1A1 | |
| SCHEMBL3524668 | 0.83 | MAPK14 (0.41) | MAPK14MAPK11PTGDR2 | |
| SCHEMBL3524656 | 0.82 | MAPK14 (0.46) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885ENPP2 1146/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885MAPK11 48/4885ENPP2 1320/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885ENPP2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.